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The tumor microenvironment consists of complex and dynamic networks of cytokines, 
growth factors and metabolic products. These contribute to significant alterations in tissue 
architecture, cell growth, immune cell phenotype and function. Increased glycolytic flux is 
commonly observed in solid tumors, and is associated with significant changes in metabolites, 
generating high levels of lactate. While elevated glycolytic flux is a characteristic metabolic 
adaption of tumor cells, glycolysis is also a key metabolic program utilized by a variety of 
inflammatory immune cells. As such lactate and the pH changes associated with lactate 
transport affect not only tumor cells but also immune cells. Here we provide an overview of 
lactate metabolic pathways and the effects lactate has on tumor growth and immune cell 
function. This knowledge provides opportunities for synergistic therapeutic approaches that 
combine metabolic drugs, which limit tumor growth and support immune cell function, 




Lactate, lactic acid, pH, tumor microenvironment, anti-tumor immunity, metabolism, 






An overview of the tumor microenvironment and tumor metabolism 
 
Human tissues are a complex mixture of parenchymal cells, immune cells, stromal 
cells, extracellular matrix and soluble factors cooperating, as components of a healthy 
microenvironment, to perform the necessary physiological and structural functions of that 
specific organ. Tumor cells are derived from these healthy cells through accumulation of 
genetic and epigenetic alterations, which lead to disruption of this finely tuned 
microenvironment. As a tumor develops it constantly interacts, physically and through secreted 
factors, with its neighboring cells, often altering their phenotype and function (Liotta and Kohn, 
2001; Balkwill, Capasso and Hagemann, 2012). The interaction between malignant and non-
malignant cells creates a dysregulated microenvironment that promotes tumor growth through 
a variety of mechanisms. A dynamic network of cytokines, growth factors, and extracellular 
matrix-degrading enzymes develops, which collectively result in significant alterations in the 
tissue architecture, dysregulated proliferation and immune dysfunction (Hanahan and 
Weinberg, 2011; Chen and Mellman, 2017). 
Proliferating cells require a constant supply of biomolecules to replicate cell structures 
and divide; these include cholesterol, glucose, glutamine, fatty acids, nucleotides and non-
essential amino acids (Vander Heiden, Cantley and Thompson, 2009). To meet the metabolic 
demands of relentless cell division, tumor clones dramatically alter their metabolic activity. 
Biosynthesis of cellular components during cell division requires a range of carbon 
intermediates, which are provided primarily by the catabolism of glucose, via glycolysis 
(Figure 1). The TCA cycle (or Kreb’s cycle) and oxidative phosphorylation are the primary 
sources of cellular energy in quiescent, regulatory and non-proliferative cells. Tumor cells 
switch from TCA, which can efficiently generate 28 molecules of ATP per molecule of 
glucose, to glycolysis, which is far less efficient, producing far fewer ATP molecules per 
 
 
molecule of glucose key carbon intermediates are produced as by-products. By converting 
pyruvate to lactate, tumor cells can prevent negative feedback signals and the consumption of 
NAD+ during mitochondrial respiration, thereby maintaining constant biosynthesis through 
glycolysis intermediates (Xie et al., 2015; Pavlova and Thompson, 2016). This phenomenon, 
termed the Warburg effect, was first observed in tumor cells ninety years ago by Otto Warburg 
(Warburg, Wind and Negelein, 1927). Due to a large amount of glucose consumed by tumor 
cells during glycolysis, metabolic by-products, in particular lactate, are produced in significant 
quantities within tumors and released into the extracellular space (Figure 1). 
In the intervening years, additional metabolic changes in tumor cells have been 
identified beyond their requirement for glucose. This includes increased reliance on glutamine, 
which provides the building blocks of nitrogen-based compounds such as nucleotides and non-
essential amino acids (Altman, Stine and Dang, 2016), and the ability to harvest free fatty acids 
from the environment (Kamphorst et al., 2013). In cases of extreme nutrient deprivation, tumor 
cells can even catabolize their proteins and lipoproteins through autophagy to liberate amino 
acids and fatty acids (Boya, Reggiori and Codogno, 2013). These tumor-associated metabolic 
alterations are maintained by altered metabolism-related gene expression, such as lactate 
dehydrogenase (LDH), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  This 
reprogramming of the metabolic circuits has significant consequences for neighboring cells 
within the tumor microenvironment, including tumor-associated fibroblasts, endothelial cells 
and immune cells  (Hanahan and Coussens, 2012; Pavlova and Thompson, 2016).  
 
The importance of lactate metabolism 
 
The generation of lactate is a cellular process necessary for maintaining glycolytic flux 
and facilitating the removal of pyruvate from the cell. The interconversion of pyruvate to lactate 
 
 
is mediated by LDH and results in the oxidation of NADH to NAD+. The lactate generated 
within a cell is then either exported from the cell via monocarboxylate transporters (MCTs) or 
converted back into pyruvate to fuel oxidative phosphorylation within the mitochondria (Figure 
1).  
Lactate levels are consistently up-regulated in a wide range of solid tumors (Goveia et 
al., 2016). Elevated lactate levels, up-regulation of LDH enzymes, and the expression of MCTs 
are prognostic of tumor progression and metastases (Zhang et al., 2015; Brand et al., 2016; 
Carmona-Fontaine et al., 2017; Payen et al., 2017). High levels of lactate in primary tumors 
are predictive of metastasis risk in head and neck cancer (Walenta et al., 1997) and cervical 
cancers (Schwickert et al., 1995). Serum levels of lactate dehydrogenase in patients with solid 
tumors are predictive of overall survival, disease progression and recurrence-free survival 
(Malhotra, Sidhu and Singh, 1986; Sagman et al., 1991; Zhang et al., 2015). Furthermore, 
suppression of lactate production within tumor cells in murine models reduces the metastatic 
ability of tumor cell lines (Hirschhaeuser, Sattler and Mueller-Klieser, 2011; Dhup et al., 2012; 
Rizwan et al., 2013).  
 
Lactate transport and signaling 
 
Lactate is transported across cell membranes via MCTs. These are a family of 
membrane transporters (also known as solute carrier 16 proteins), of which four members are 
proton-linked symporters (MCT1-MCT4) with varying tissue expression (Halestrap, 2013). 
Tumors and immune cells predominantly express MCT1 and MCT4 and this expression profile 
appears to be characteristic of highly glycolytic cells (Pinheiro et al., 2010). MCTs passively 
transport lactate and a co-transported proton across the cell membrane. In situations where 
extracellular concentrations of either lactate or protons are elevated, these MCTs also facilitate 
 
 
the transport of lactate back into the cellular cytoplasm. This facilitates the cell-cell lactate 
shuttles, whereby a glycolytic cell produces lactate, which in turn is taken up and utilized as an 
energy source by a neighboring oxidative cell (Sonveaux et al., 2008; Draoui and Feron, 2011).  
Extracellular lactate produced by glycolytic cells can also enter the circulation through 
capillaries or draining lymph. This lactate is subsequently removed from the circulation in the 
liver and kidney via gluconeogenesis (also referred to as the Cori cycle). Circulating lactate is 
transported into hepatocytes and renal cortex cells via MCTs and is converted via pyruvate 
back into glucose (Gerich et al., 2001; Roef et al., 2003). Gluconeogenesis results in the 
consumption of ATP molecules generated from oxidative phosphorylation and the glucose 
produced is either stored as glycogen in hepatocytes or exported back into the circulation where 
it can once again be utilized as a fuel source by glycolytic cells. 
In addition to its role in glycolysis, lactate also possesses signaling and suppressor 
functions. Lactate is able to bind to the G-protein-coupled receptor GPR81 (Cai et al., 2008), 
which reduces cAMP and protein kinase A signaling, reducing proinflammatory cytokine 
production and inducing expression of regulatory factors such as IL-10, retinoic acid and 
indoleamine 2,3-dioxygenase (IDO) (Hoque et al., 2014; Ranganathan et al., 2018). Lactate 
can also directly bind to the transmembrane domain of the mitochondrial antiviral-signaling 
protein (MAVS). MAVS is an innate intracellular sensor of double-stranded RNA (Seth et al., 
2005). Binding of lactate to MAVS prevents type I IFN production (Zhang et al., 2019). Lactate 
binding to MAVS prevents protein aggregation and provides a mechanistic link between 
metabolism and type I interferon responses, limiting interferon production in cells undergoing 
anaerobic glycolysis.  
 




While elevated glycolytic flux is a well-documented characteristic of tumor cells, 
certain tumor cell subpopulations can utilize this lactate to fuel oxidative phosphorylation (Hui 
et al., 2017). Highly glycolytic tumors have been shown to share space with low glycolytic 
neighboring tumors, which use lactate as a fuel source for mitochondrial respiration obtained 
via lactate shuttling from their glycolytic neighbors (Sonveaux et al., 2008). In breast cancer, 
signals from tumor cells can also lead to increased lactate production by stromal cells 
(Whitaker-Menezes et al., 2011). This lactate is then taken up by tumor cells, converted to 
pyruvate and shuttled into the TCA cycle to fuel oxidative phosphorylation. The use of lactate 
as a fuel source requires an intact TCA cycle and functional mitochondria to metabolize the 
pyruvate generated.  
While these studies highlight the importance of increased glycolytic flux in tumor cell 
survival and cancer progression, the exact location of this lactate remains somewhat uncertain 
and further research is required to directly quantify lactate levels and pH within the tumor 
microenvironment (García-Cañaveras, Chen and Rabinowitz, 2019). Direct measurements of 
the interstitial fluid of tumors via both in vivo and ex vivo methods indicate only a modest 
increase of lactate, in contrast to the dramatically elevated levels of lactate observed in whole 
tumor tissues (García-Cañaveras, Chen and Rabinowitz, 2019). These conflicting data can be 
reconciled if lactate preferentially accumulates within tumor cells.  The proton gradient 
generated by the low pH of the tumor microenvironment, and relative alkaline intracellular pH 
of tumor cells, may favor the transport of lactate into tumor cells, thereby limiting lactate 
accumulation within the extracellular microenvironment (García-Cañaveras, Chen and 
Rabinowitz, 2019). Understanding the composition of the tumor microenvironment is central 
to untangling the individual (and potentially synergistic) effects of lactate and pH on tumor 




Impact of lactate and pH on the tumor microenvironment 
 
Lactate and pH have additional impacts on the tumor microenvironment beyond 
providing alternative energy sources for oxidative tumor cell subpopulations. Lactate has been 
shown to play several roles in reorganizing the physical tumor architecture and the immune 
landscape of many tumor types (Romero-Garcia et al., 2016). Lactate and reduced pH can 
promote tumor cell survival under conditions of nutrient deprivation. Glucose deprivation of 
the breast tumor cell line 4T1, in the absence of lactate, results in rapid apoptosis. In contrast, 
high concentrations of lactate induce cell cycle arrest and autophagy, enabling 4T1 cells to 
survive for extended periods when deprived of glucose (Wu et al., 2012). Lactate can act on 
vascular endothelial cells, activating the hypoxia-inducible factor-1a (HIF-1a) pathway to 
induce vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) 
expression, as well as stimulating autocrine NF-κB/IL-8 (CXCL8) signaling to drive 
angiogenesis (Vegran et al., 2011; Sonveaux et al., 2012).  
Lactate also acts on tumor-associated fibroblasts to induce the production of hyaluronic 
acid, which promotes the migration and extravasation of tumor cells (Stern et al., 2002). 
Perhaps surprisingly, tumors can also influence sites distant from the primary tumor via 
metabolites. Lactate is enriched in tumor-draining lymph nodes and drives a pro-tumorigenic 
fibroblast phenotype in fibroblastic reticular cells by inducing activation and mitochondrial 
dysfunction in a pH-dependent manner (Riedel et al., 2018).   
 
The emerging links between metabolism and effector immune responses 
 
The importance of energy production and biosynthesis for the metabolic demands of 
activated proliferating immune cells was first documented in early studies on macrophages and 
 
 
neutrophils (Alonso and Nungester, 1956; Newsholme et al., 1986). However, the full extent 
of the links between metabolism and immune responses are only recently appreciated. Beyond 
simply meeting the energy and biosynthesis demands of activated immune cells, it is now clear 
that metabolic pathways directly regulate immune cell effector function, and the metabolic 
intermediates generated play an essential role in coordinating overall immune responses. While 
elevated glycolytic flux is a characteristic metabolic adaption of tumor cells, glycolysis is also 
a key metabolic program utilized by a variety of inflammatory immune cells, including 
cytotoxic lymphocytes, which migrate into the tumor microenvironment. 
The up-regulation of glycolytic machinery is a common feature amongst rapidly 
proliferating inflammatory immune cells (MacIver et al., 2008; Buck, O’Sullivan and Pearce, 
2015; Assmann et al., 2017). Activated immune cells bear a striking resemblance to 
proliferating tumor cells. Immune cells require rapid production of carbon intermediates to fuel 
proliferation, production of effector molecules and energy-intensive cell processes, such as 
migration and phagocytosis. While glycolysis is relatively inefficient in the generation of ATP, 
it enables the reduction of NAD+ to NADH as well as the generation of intermediates essential 
for sustaining immune cell biosynthesis (O’Neill, Kishton and Rathmell, 2016). 
Proinflammatory and effector immune cells display a dramatic up-regulation of glycolysis, 
together with an increased use of the pentose phosphate, fatty acid synthesis and amino acid 
metabolic pathways (O’Neill, Kishton and Rathmell, 2016). This distinct metabolic program 
supports inflammatory cytokine production, proliferation, reactive oxygen species (ROS) 
production, nitric oxide production and effector cell differentiation.  
 Up-regulation of the TCA cycle together with increased fatty acid oxidation, which 
reduces intracellular lipid accumulation, are associated with suppressive immune responses, 
the generation of immune tolerance, and the promotion of memory cell generation and survival 
(Yaqoob, 2003; Pearce et al., 2009; Michalek et al., 2011). These metabolic pathways are up-
 
 
regulated in macrophages with an M2 polarization (Jha et al., 2015), regulatory T helper cells 
(Michalek et al., 2011) and quiescent memory T cells (van der Windt et al., 2013). 
Intriguingly several metabolic intermediates and metabolic enzymes have been shown 
to have secondary signaling functions in immune cells (Tannahill et al., 2013; Mills et al., 
2018; Mills et al., 2018; Ryan et al., 2018). This additional level of complexity facilitates the 
direct regulation of immune responses by metabolic processes. Hexokinase 1 has been shown 
to directly interact with and activate the NLRP3 inflammasome, leading to caspase activation 
and the processing of pro-IL-1β (Moon et al., 2015). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) binds to mRNA encoding interferon γ (IFNγ) and represses its 
translation; the switch to glycolysis that occurs in response to T cell activation leads to the 
dissociation of GAPDH allowing for translation of IFNγ (Chang et al., 2013). Metabolic 
intermediates are also capable of regulating immune responses. Succinate, a metabolic 
intermediated of the TCA cycle, is dramatically increased upon activation of pro-inflammatory 
macrophages. Increased succinate levels stabilize HIF-1α, which is required for maximal IL-
1b production by macrophages (Tannahill et al., 2013). Conversely, the metabolite itaconate 
is increased as part of an anti-inflammatory response upon diversion of aconitate away from 
the TCA cycle during pro-inflammatory macrophage activation. Itaconate alkylates KEAP1 
leading to activation of the anti-inflammatory transcription factor Nrf2, which regulates 
inflammation and type I interferon responses (Mills et al., 2018). In the context of these 
intimate links between metabolism and immune cell responses, the impact of lactate on 
immune cell function is of particular relevance for effective tumor immunity (Mills, Kelly and 
O’Neill, 2017).   
 




Elevated lactate and decreased pH affect the phenotype and function of immune cells, 
polarizing the innate immune system toward tolerance and immunosuppression. It is important 
to note that lactate and pH can act both independently and synergistically to alter immune cell 
function.  
Macrophages can be broadly divided into M1-like inflammatory macrophages and M2-
like regulatory macrophages (Murray and Wynn, 2011). Lactate acts upon macrophages, 
independently of pH, up-regulating markers associated with an M2-like phenotype and down-
regulating markers associated with M1-like macrophages (Figure 2). Lactate induces HIF-1a 
signaling and drives arginase-1 and VEGF expression (Colegio et al., 2014) and synergizes 
with hypoxia to drive activation of MAPK signaling and arginase-1 expression in tumor-
associated macrophages (Carmona-Fontaine et al., 2017). Lactate also signals via the GPR81 
receptor on macrophages to reduce NFκB and inflammasome activation, resulting in reduced 
production of proinflammatory cytokines including IL-6, IL-1b, and TNFa (Figure 3) (Goetze 
et al., 2011; Hoque et al., 2014; Ranganathan et al., 2018). At the same time, GPR81 signaling 
in macrophages drives the expression of immune suppressive factors associated with M2-like 
phenotypes including IL-10, retinoic acid and IDO (Hoque et al., 2014; Ranganathan et al., 
2018). 
Macrophages are capable of shuttling lactate from the extracellular microenvironment 
via MCTs. The accumulation of intracellular lactate reduces RIG-I-like receptor signaling 
independently of pH by directly binding to the adaptor protein MAVS (Zhang et al., 2019). 
This blocks localization of MAVS to mitochondrial membranes and thereby inhibits RIG-I 
activation (Zhang et al., 2019). At a transcriptional level, changes in macrophage gene 
expression induced by lactate vary depending on the presence of lactate and/or reduced pH 
(Peter et al., 2015). Lactate synergizes with low pH to induce IL23A transcription in 
monocytes, promoting the IL-23/IL-17 proinflammatory pathway (Shime et al., 2008), and 
 
 
likewise TNF and ROS suppression upon exposure to high levels of lactate requires the 
synergistic effects of both lactate and decreased pH (Dietl et al., 2010) (Figure 2). 
A synergistic effect of lactate and decreased pH is also observed on dendritic cells 
(Gottfried et al., 2006; Nasi et al., 2013) and T cells (Fischer et al., 2007). Lactate together 
with a decreased pH inhibits dendritic cell differentiation as measured by CD1a, HLA-DR and 
CD86 expression (Gottfried, 2006; Nasi et al., 2013). This effect was not recapitulated by 
acidic pH alone (via HCl) or by the presence of lactate at pH 7.4 (Gottfried, 2006), with lactate 
and decreased pH acting synergistically to induce IL-10 production and suppress IL-12 
production from dendritic cells (Nasi et al., 2013). In cytotoxic T lymphocytes, lactate and 
decreased pH induces apoptosis after 24 hours and decreases IFNg and IL-2 production, effects 
not observed upon HCl treatment alone (Fischer et al., 2007). In this study, cytotoxic T 
lymphocyte proliferation and cytotoxic function appeared to be driven mainly by the decrease 
in pH associated with lactic acid treatment (Fischer et al., 2007) and several other studies have 
highlighted the important effects of acidic microenvironments on immune cell function. 
In vitro studies have highlighted the important effect of pH changes associated with 
lactate export on T cell and NK cell function (Fischer et al., 2007; Husain et al., 2013a; Brand 
et al., 2016; Pötzl et al., 2017; Harmon et al., 2019) (Figure 2). T cells treated with low pH 
display reduced activation and cytokine production (Brand et al., 2016), while NK cells 
exposed to acidic microenvironment display reduced granzyme B and reduced cytotoxic 
effector functions (Husain et al., 2013b). Acidification of the tissue microenvironment causes 
a drop in intracellular pH and induces the selective cell death of T cells and NK cells, by driving 
increased mitochondrial dysfunction and mitochondrial ROS production (Figure 3) (Brand et 
al., 2016; Harmon et al., 2019). Reversing tumor acidosis has been shown to restore NK cell 
function and improve anti-tumor activity in vivo (Pötzl et al., 2017) and targeted inhibition of 
mitochondrial ROS production can promote NK cell survival (Harmon et al., 2019) 
 
 
highlighting the potential for therapeutic interventions targeting metabolic pathways to 
improve immune cell function.  
 
Opportunities to target lactate metabolism in cancer 
 
The availability of immunotherapies for cancer treatment is exploding, yet many 
cancers and/or patients are still unresponsive. Complementary immune-activating therapies are 
required to increase response rates. Targeting metabolic pathways in tumors has multiple 
potential beneficial effects. Depriving tumor cells of essential nutrients limits their biosynthetic 
and proliferative capacity, reducing tumor growth dramatically. This is not a new concept in 
oncology where therapeutics targeting metabolism, such as methotrexate, have been used in 
the clinic for decades (Chabner and Roberts, 2005).  Due to the importance of tumor-derived 
metabolites as a component of the tumor microenvironment, targeting metabolism can create 
a more hospitable microenvironment for the immune system to work within and induce stress 
response pathways in tumor cells (Renner et al., 2017).  
The broad spectrum of receptors, transporters, and catalyzing enzymes involved in 
tumor metabolism has led to the development of an array of metabolic therapies, which are 
now beginning to enter the clinic, with varying degrees of success (Tennant, Durán and 
Gottlieb, 2010; Galluzzi et al., 2013). While an attractive target, metabolic therapies can also 
have side effects, specifically on the immune system. Metabolic changes underpin many of the 
immune functions we associate with tumor immunity (O’Neill, Kishton and Rathmell, 2016), 
in particular T cell and NK cell activation and effector function (Buck, O’Sullivan and Pearce, 
2015; Assmann et al., 2017). Indeed, treatments targeting metabolism, such as methotrexate, 
are also detrimental to the immune response. One of the other major clinical indications for the 
use of methotrexate is in autoimmunity where it functions as an immunosuppressant (Cutolo 
 
 
et al., 2001). Any metabolic therapeutic approach should therefore aim to target pathways 
differentially used by tumor and non-tumor cells.  
The glycolysis pathway provides the biochemical intermediates for several essential 
processes required for tumor cell growth and division (Xie et al., 2015), and the glycolytic 
pathway has been highlighted as a potential therapeutic target in cancer (Doherty and 
Cleveland, 2013; Ganapathy-Kanniappan and Geschwind, 2013). However, our immune 
response is also dependent on glycolysis for the acquisition of effector functions, especially T 
and NK cells, which are the main mediators of tumor immunity (MacIver et al., 2008; Buck, 
O’Sullivan and Pearce, 2015; Assmann et al., 2017). Clinical trials of 2-deoxyglucose (2-DG), 
a glucose analog that reduces the rate of glycolysis in both tumor cells and immune cells, 
showed limited effects on tumor progression, despite promising pre-clinical data (Raez et al., 
2013). More recently pre-clinical studies using koningic acid to partially inhibit GAPDH 
induced a cytotoxic response in cancer cell lines without impacting on tumor immunity (Liberti 
et al., 2017). This study highlights the precision and specificity required to target this pathway 
without impacting on immune cell function.  
The production and secretion of lactate can also be targeted via several alternative 
therapeutic strategies that avoid the need to completely inhibit glycolysis. These alternative 
strategies may hold promise in avoiding the detrimental effects of complete inhibition of 
glycolysis on immune cells. Targeting either lactate transport via MCTs (Sonveaux et al., 2008, 
2012; Vegran et al., 2011; Noble et al., 2017) or lactate dehydrogenase enzymes (Le et al., 
2010; Manerba et al., 2012) prevents the release of lactate from tumor cells and induces 
cytotoxic responses. A study using an early non-selective MCT inhibitor suggests inhibition of 
T cell function may still be an issue (Fischer et al., 2007), and further studies are required to 
assess the effects of novel selective MCT and lactate dehydrogenase inhibitors on immune cell 
function. A specific MCT1 inhibitor, AZ3965, has shown promise in pre-clinical studies and 
 
 
is currently being trialed in solid tumors including gastric cancer and lymphoma (NCT 
01791595). Furthermore, an MCT4 inhibitor is in preclinical development (AZD0095), which 
does not affect T cell function and when combined with checkpoint therapy improves tumor 
rejection in an MC-38 murine colon cancer model (Critchlow et al., 2019). 
The hydrogen ions co-transported with lactate, which act to decrease the pH of the 
tumor microenvironment and suppress immune cell function, can also be therapeutically 
targeted. Significant clinical improvement has been reported with the use of systemic 
bicarbonate buffering, which neutralizes tumor acidity, reduces tumor invasiveness and 
improves the immune response (Corbet and Feron, 2017; Ibrahim-Hashim et al., 2017; Pötzl 
et al., 2017). Despite these positive results from pre-clinical studies, translation of these 
strategies into clinical trials is limited by the potential for adverse events, including electrolyte 
imbalance, respiratory depression and progressive vascular calcification (Adeva-Andany et al., 
2014). The targeted use of bicarbonate buffering has been trialed in patients receiving trans-
arterial chemoembolization for hepatocellular carcinoma, which improved tumor response 
rates, although had minimal effect on overall survival (Chao et al., 2016). 
Decreasing intracellular pH is a consequence of the acidic microenvironment tumor-
infiltrating immune cells migrate into. This decrease in pH is associated with increased 
mitochondrial ROS production and immune cell apoptosis (Brand et al., 2016; Harmon et al., 
2019). Reducing the accumulation of mitochondrial ROS using ROS scavengers can protect 
immune cells from pH-induced apoptosis ex vivo (Harmon et al., 2019). The use of 
mitochondria-targeted scavengers has shown some efficacy in murine models of cancer, 
although in these studies the effect was attributed to a direct effect of tumor cell survival 
(Nazarewicz et al., 2013; Porporato et al., 2014). It remains to be seen if some of these anti-
tumor effects of mitochondria-targeted scavengers in vivo are also mediated by improvements 
in immune cell function. 
 
 
The availability of immunotherapies for cancer treatment has revolutionized the field 
of oncology. However, many cancers and/or patients fail to respond to these immune-activating 
therapies. This could be due to the inhospitable environment created by tumor metabolism, 
creating a toxic microenvironment for even engineered immune cells. Immunotherapies, either 
checkpoint inhibitors or cellular therapies, rely on the ability of immune cells to alter and 
maintain their metabolism to carry out effector functions. As discussed in this chapter, tumors 
have adapted to avoid just this. Therefore, complementary metabolic therapies are required to 
enhance immune-based treatments and improve patient response in solid tumors. Therapeutic 
approaches taking into consideration the metabolic heterogeneity of the tumor 
microenvironment and the metabolic demands of tumor-infiltrating immune cells in 
personalized models hold much promise. By harnessing the synergistic anti-tumor effects of 
limiting tumor growth as well as augmenting local immune cells, these metabolic approaches 
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Figure 1. Glycolytic intermediates fuel biosynthesis of essential molecules for tumor cell 
proliferation. Tumor cells favor glycolysis due to the range of intermediates produced and the 
ability to produce the reducing molecule NAD+ by converting pyruvate to lactate. Detailed are 
the biochemical intermediates produced by glycolysis which are used for biosynthesis of 
essential molecules for cell proliferation. Dashed lines denote intermediates not shown. NAD+, 
oxidized nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine 
dinucleotide; MCT, monocarboxylate transporter; TCA, tricarboxylic acid cycle; GLUT, 
glucose transporter. 
  
Figure 2. Immunological consequences of elevated lactate and decreased pH in the tumor 
microenvironment. Lactate and reduced pH have differential and synergistic effects on 
immune cells in the tumor microenvironment. Effects mediated by lactate alone are written in 
blue, by pH alone in red and combined effects in black. HIF1a, hypoxia-inducible factor 1a, 
IDO, indoleamine-2,3-deoxygenase, NK, natural killer, ROS, reactive oxygen species, TNFa, 
tumor necrosis factor a, VEGF, vascular endothelial growth factor. 
  
Figure 3. Intracellular effects of uptake of lactate and decreased pH in the tumor 
microenvironment. Lactate can signal through GPR81, resulting in decreased cAMP and loss 
of PKA signaling. Alternatively, lactate can be absorbed into the cell, with protons, via MCTs, 
causing decreased intracellular pH, mitochondrial dysfunction and reduced metabolic output. 
Finally, protons can be directly internalized by proton transporters, resulting in reduced pH and 
mitochondrial dysfunction. cAMP, cyclic adenosine monophosphate, ATP, adenosine 
triphosphate, GPR81, G protein-coupled receptor 81, MCT, monocarboxylate transporter, 
ROS, reactive oxygen species. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
